Form 4 for EYPT EyePoint, Inc.
Accepted 2024-01-16 00:00:00 ET · period of report 2024-01-11 · accession 0001562180-24-000466 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-01-16 | 2024-01-11 | EYPT | Liu Ye | Dir | S - Sale | $19.45 | -1.91M | 100.2K | -95% | -$37.16M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.001 par value | 2024-01-11 | S | D | 1,910,500 | $19.45 | 100,221 | I Ocumension Therapeutics | — | — | (F1) The shares are held by Ocumension Therapeutics. The reporting person is Chief Executive Officer and a Director of Ocumension Therapeutics. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |